NCT04734275 is a Phase 1 clinical trial of AZD5718 in Chronic Kidney Disease, sponsored by AstraZeneca.

Who is sponsoring NCT04734275?

NCT04734275 is sponsored by AstraZeneca.

What drugs are being tested in NCT04734275?

Interventions in NCT04734275: AZD5718.

What condition does NCT04734275 study?

NCT04734275 studies Chronic Kidney Disease.

Is NCT04734275 still recruiting?

NCT04734275 is currently completed. Last updated 6 December 2021.

Last reviewed 2021-12-06 · How we verify

NCT04734275

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers

Completed Phase 1 Last updated 6 December 2021

What this trial tests

Phase 1 trial testing AZD5718 in Chronic Kidney Disease in 16 participants. Completed in 25 March 2021.

Timeline

1 February 2021

Primary endpoint
25 March 2021

25 March 2021

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	1 February 2021
Primary completion	25 March 2021
Estimated completion	25 March 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

AZD5718 — full drug profile →

Conditions studied

Chronic Kidney Disease — all drugs for Chronic Kidney Disease →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 55, any sex, with Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be a randomised, open-label, 3-period, 3-treatment, single-dose, crossover study in healthy subjects The study will be performed at a single study centre in the United Kingdom.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of AZD5718

Trials testing the same drug.

NCT04601467 — PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE · Phase 2 · terminated
NCT04492722 — A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease · Phase 2 · terminated
NCT04492709 — A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects · Phase 1 · completed
NCT03317002 — AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery D · Phase 2 · completed

Other recruiting trials for Chronic Kidney Disease

Currently open trials in the same condition.

NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04734275 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 6 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04734275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing